Results 181 to 190 of about 106,748 (296)

Case Report: Diagnostic pitfall and biomarker-guided therapy in CD20-negative Epstein-Barr virus-positive diffuse large B-cell lymphoma. [PDF]

Front Immunol
Wen J, Zhao C, Chen S, Chen X, Lv Q, Liu W, Wang J, Chen D.   +7 more
europepmc   +1 more source

Increased anergic B cells and decreased antibody‐secreting cells during romiplostim treatment in patients with immune thrombocytopenia

British Journal of Haematology, EarlyView.
Summary Patients with immune thrombocytopenia (ITP) exhibit substantial heterogeneity in treatment responses. Approximately 30%–50% of patients maintain remission after discontinuation of thrombopoietin receptor agonists (TPO‐RA), suggesting immunomodulatory effects beyond enhanced thrombopoiesis.
Vivianne S. Nelson, Rebeca Gutiérrez‐Cózar, Rebecca Cornelis, S. Marieke van Ham, Anja ten Brinke, Rick Kapur   +5 more
wiley   +1 more source

Circulating Extracellular Vesicle Biomarkers in Chronic Lymphocytic Leukemia: A Preliminary Study on Their Diagnostic, Prognostic, and Predictive Relevance. [PDF]

Biomolecules
Laurenzana I, Caivano A, Di Ciancia A, Villani O, Maietti M, De Stradis A, D'Arena G, Nozza F, De Luca L, Lamorte D.   +9 more
europepmc   +1 more source

Trends and socio‐economic disparities in chronic lymphocytic leukaemia 2014–2022: An England‐wide cohort study from the UNCOVER group

British Journal of Haematology, EarlyView.
Summary To re‐evaluate chronic lymphocytic leukaemia (CLL) epidemiology in the era of modern therapy, data were extracted from the English National Cancer Registration Dataset (NCRD). A total of 34 427 consecutive diagnoses of CLL were recorded (2014–2022), the largest European dataset on record.
Temitope Erinfolami, Amelia Fisher, Indrani Karpha, Yeong Lim, Nurunnahar Akter, Toyyib Abdulkareem, Brogan Johnston, Catrin Tudur Smith, Hilary Lindsay, Shaun Bowden, Debbie Yates, Lelia Duley, Renata Walewska, Stella Williams, David Allsup, Nagesh Kalakonda, Mark Bishton, Andrew Pettitt, Nicolas Martinez‐Calle   +18 more
wiley   +1 more source

Age and treatment class modify inflammatory risk after disease-modifying therapy discontinuation in older people with MS. [PDF]

J Neurol Neurosurg Psychiatry
Carvajal R, Marcialis C, Tur C, Otero-Romero S, Roos I, Pappolla A, Novak F, Cobo-Calvo A, Ariño H, Arrambide G, Bollo L, Casallas-Vanegas A, Castilló J, Comabella M, Driemeyer C, Elosua I, Fadrique C, Galán I, Grávalos M, La Puma D, Masot A, Midaglia L, Molina-Goicoechea M, Mongay-Ochoa N, Rodríguez-Acevedo B, Río J, Tagliani P, Vidal-Jordana A, Vilaseca-Jolonch A, Zabalza A, Pugliatti M, Sastre-Garriga J, Kalincik T, Montalban X, Tintore M.   +34 more
europepmc   +1 more source

SENIOR‐IPI: An easily applicable prognostic index for first‐line large B‐cell lymphomas patients >80 years treated with curative intent

British Journal of Haematology, EarlyView.
Summary Using LYmphoma Study Association clinical trials combining 438 first‐line large B‐cell lymphomas (LBCL) patients >80 years old, we defined SENIOR‐IPI, an easily applicable prognostic index for this elderly population treated with an anti‐CD20‐miniCHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)‐based regimen.
Sydney Dubois, Fanny Cherblanc, Aurelien Belot, Lucie Oberic, Hervé Ghesquières, Corinne Haioun, Hervé Tilly, Jean‐Philippe Jais, Fabrice Jardin   +8 more
wiley   +1 more source

Correction: Obinutuzumab as salvage anti-CD20 therapy in poly-refractory difficult-to-treat seropositive rheumatoid arthritis. [PDF]

Rheumatol Adv Pract
europepmc   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad   +25 more
wiley   +1 more source

Radiotherapy in Combination with CD20×CD3 Bispecific Antibodies for B-Cell Lymphoma: Biological Rationale, Current Evidence, and Open Questions. [PDF]

Cancers (Basel)
Ciammella P, Bavieri A, Nizzoli ME, Alì E.   +3 more
europepmc   +1 more source

Evidence for the use of anti-CD20 therapeutic antibodies in immune thrombotic thrombocytopenic purpura management: a review. [PDF]

Front Pharmacol
Halkidis K, Meng C, Snyder J.
europepmc   +1 more source